Superiority of letrozole over tamoxifen in the first-line treatment of metastatic breast cancer patients with normal serum HER-2/neu levels:: question of tamoxifen resistance -: In Reply

被引：0
|
作者：
Lipton, A [1 ]
Leitzel, K
Demers, L
Harvey, HA
Ali, SM
Chaudri-Ross, HA
Wyld, P
Brady, C
Carney, W
机构：
[1] MS Hershey Med Ctr, Hershey, PA USA
[2] Vet Adm Med Ctr, Lebanon, PA USA
[3] Novartis Pharma AG, Basel, Switzerland
[4] Novartis Pharmaceut Corp, E Hanover, NJ USA
[5] Bayer Corp, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2003年 / 21卷 / 24期
关键词：
D O I：
10.1200/JCO.2003.99.187
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：4657 / 4657
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of pertuzumab combined with trastuzumab and docetaxel as a first-line treatment for HER-2 positive metastatic breast cancer
    Leung, Henry W. C.
    Chan, Agnes L. F.
    Muo, Chih-Hsin
    Leung, John Hang
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2018, 18 (02) : 207 - 213
  • [42] Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the international letrozole breast cancer group - Reply
    Mouridsen, H
    Chaudri-Ross, HA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (15) : 3200 - 3201
  • [43] Maintenance bevacizumab after first-line treatment in HER2-negative metastatic breast cancer patients
    Fabi, A.
    Russillo, M.
    Metro, G.
    Papaldo, P.
    Nistico, C.
    Ferretti, G.
    Cuppone, F.
    D'Auria, G.
    Giannarelli, D.
    Cognetti, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Capacitabine/trastuzumab for the first-line treatment of patients with HER2-positive metastatic breast cancer (MBC)
    Chan, A.
    Yamamoto, D.
    Bell, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [45] Prognostic value of HER-23/neu and p53 expression in node-positive breast cancer.: HER-2/neu effect on adjuvant tamoxifen treatment
    Climent, MA
    Seguí, MA
    Peiró, G
    Molina, R
    Lerma, E
    Ojeda, B
    López-López, JJ
    Alonso, C
    BREAST, 2001, 10 (01): : 67 - 77
  • [46] Randomized phase III trial of exemestane or tamoxifen in first-line hormonal treatment of postmenopausal women with metastatic breast cancer.
    Chernozemsky, I
    Kalinov, K.
    Tzekov, H.
    Racheva, M.
    Hristova, S.
    Tomova, A.
    Koynova, T.
    Taskova, V
    Boideva, L.
    Eniu, A.
    Krasteva, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S119 - S119
  • [47] Phase I-II study of liposomal doxorubicin (Myocet®), docetaxel and trastuzumab as first-line treatment of patients with her-2/neu positive locally-advanced or metastatic breast cancer
    Amadori, D.
    Gasparini, G.
    Di Blasio, B.
    Di Costanzo, F.
    Lunardi, G.
    Vannozzi, M. O.
    Serra, P.
    Milandri, C.
    ANNALS OF ONCOLOGY, 2005, 16 : 12 - 12
  • [48] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [49] Patients with elevated serum HER-2/neu show increased response to Herceptin therapy in metastatic breast cancer.
    Schwartz, MK
    Ghani, F
    Dnistrian, AM
    Kish, L
    Schwartz, DC
    Armstrong, G
    CLINICAL CHEMISTRY, 2002, 48 (06) : A20 - A20
  • [50] Evaluation of HER-2/neu in serum and tissue of primary and metastatic breast cancer patients using an automated enzyme immunoassay
    Dittadi, R
    Zancan, M
    Perasole, A
    Gion, M
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2001, 16 (04): : 255 - 261
12345